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Summary The risks of second primary cancer were analysed in 2846 patients with Hodgkin's disease treated
within the British National Lymphoma Investigation during 1970-87. The relative risk (RR) of leukaemia was
significantly greater in women (RR = 30.1; 95% confidence limits (CL) 13.0-59.5) than in men (RR = 10.9;
95% CL 4.7-21.5), and showed a significant trend of greater risk with younger age at first treatment
(P<0.001). The relative risk of solid cancers was similar between the sexes, but again significantly greater at
young than at older ages of first treatment (P<0.01). Non-Hodgkin's lyrrphoma relative risks, although not
related to sex or age, were significantly related to histology of the o;:iginal Hodgkin's disease, and were
greatest after lymphocyte predominant Hodgkin's disease (RR = 55.6; 95% CL 18.0 - 129.7). The relative risk
of second cancers did not vary significantly according to whether or not splenectomy had been performed.
Leukaemia risk was non-significantly greater after splenectomy than with no splenectomy, which accorded
with previous evidence of a modest increased risk associated with this operation.
If the greater relative risk of solid second cancers after treatment at young than at older ages persists with
longer follow-up, the incidence rates of these second primaries in patients treated young for Hodgkin's disease
will become very substantial as they age. This emphasises the need to maintain long-term follow-up surveil-
lance of young Hodgkin's disease patients apparently cured of their disease, and to continue to develop new
less carcinogenic treatment regimes.
An increased risk of second cancers after modern intensive
treatment for Hodgkin's disease is well established (Kaldor et
al., 1987). After radiotherapy there are raised risks of several
solid tumours (Boivin & O'Brien, 1988), and probably also of
leukaemia (Boivin et al., 1984; Tucker et al., 1988; Van
Leeuwen et al., 1989). After chemotherapy, a very high risk
of acute or non-lymphocytic leukaemia has been shown
(Pedersen-Bjergaard et al., 1987; Tucker et al., 1988), and in
a recent study we found solid cancer risk also to be increased
(Swerdlow et al., 1992). The risks of these second primary
malignancies in relation to host factors, and subtype and
stage of Hodgkin's disease, are unclear. Investigation of this
needs data sets with large numbers of patients, and the
results which have been published have been inconsistent
(Tucker et al., 1988; Van der Velden et al., 1988; Kaldor et
al., 1990; Henry-Amar et al., 1990). We present here analyses
of these factors in data from the British National Lymphoma
Investigation (BNLI), a long-established, large clinical col-
laborative investigation whose files have detailed treatment
data and virtually complete follow-up information.
Materials and methods
The BNLI is a collaborative group of over 60 participating
centres in the UK, which has collected detailed data on the
diagnosis, therapy and follow-up of lymphoma patients treat-
ed at the centres since 1970. Most of the patients were in
randomised controlled trials of treatment. The present
analyses relate to all BNLI patients with Hodgkin's disease
aged 10 years and above first treated between 1 February
1970 and 31 December 1987. The patients come from all
parts of the UK, with sizeable numbers from almost all
regions. They constitute about 10% of all patients with the
disease incident in the UK during the study period, but are
not a population-based sample. Most but not all of the
patients have been entered into the International Database
on Hodgkin's disease (Henry-Amar et al., 1990), but with
less-complete and slightly shorter follow-up than here, and
with less extensive treatment information, relating only to
initial treatments. Diagnoses of Hodgkin's disease in the
patients in the study had in all instances been confirmed by
the BNLI pathology panel. Data on all treatments for Hodg-
kin's disease, both at presentation and for relapses, were
available in the BNLI files. Treatment data were available
even if the patient had transferred to a centre outside the
BNLI. No patient had received treatment before entry to a
BNLI centre. Treatments and person-years at risk after
incidence of a second primary cancer were excluded from the
analyses. Follow-up was by several different mechanisms, in
order that it should be as complete as possible. Details are
given in Swerdlow et al. (1992). In brief, the BNLI receives
notification of second cancers, deaths and emigrations from
clinical follow-up, conducted 6-monthly for the first 5 years
after entry to care within the BNLI, and annually thereafter,
unless greater frequency is clinically necessary. Patients who
have left the care of BNLI centres are followed via their new
doctor, or failing that by direct contact with the patient. The
BNLI pathology panel reviews biopsy material from appar-
ent relapses of Hodgkin's disease, and sometimes finds
second primary cancers as a result, which are added to the
BNLI files. For the present analyses, additionally, each con-
sultant was mailed to check that all second cancers known to
him or her had been reported, and nine regional cancer
registries checked lists of study subjects resident in their areas
against cancer registration files to find second cancers and
deaths. Details of patients whose vital status was still un-
known after the above procedures were sent to be traced at
the National Health Service Central Register, a virtually
complete population register of England and Wales, which
records deaths, emigrations, other losses to follow-up, and
since 1971 cancer registrations.
Diagnoses of second primary non-Hodgkin's lymphoma
were reviewed by the BNLI pathology panel. The diagnoses
taken for other second primary cancers were those made by
pathologists at the referral centres, except that in seven in-
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stances only death certificate or clinical diagnoses were avail-
able. Cancer sites were coded according to the International
Classification of Diseases (ICD) eighth revision (WHO, 1967)
for cases incident before 1979, and ninth revision (WHO,
1977) for cases incident in 1979 onwards. Only neoplasms
within the malignant codes of the ICD (ICD8 140-208;
ICD9 140-209) were analysed.
Histories of treatment for Hodgkin's disease were divided
into four groups for analysis: ever treatment with chemo-
therapy which included an alkylating agent but never treat-
ment with radiotherapy; ever alkylating chemotherapy plus
ever radiotherapy (at the same or a different time); extensive
radiotherapy (i.e. mantle, or inverted Y, or total nodal
irradiation) but never alkylating chemotherapy; and local
radiotherapy but never alkylating chemotherapy. Fifteen
patients who could not be allocated to any of these cate-
gories, because the type of chemotherapy was not fully
specified in the BNLI files, or neither chemotherapy nor
radiotherapy had been given, were excluded from the
analyses by treatment type. Staging and histology of Hodg-
kin's disease were classified in conventional ways (Carbone et
al., 1971; Bennett et al., 1985). Number of courses of treat-
ment was recorded, where a 'course' described a fixed treat-
ment regimen, usually used for about 6 months, after which
the treatment was stopped.
Risks of second cancers were analysed to 31 December
1987. Person-years at risk by sex, age and calendar year were
calculated to that date, or to death, loss to follow-up or
incidence of second primary cancer if these occurred earlier.
In analyses of risk in relation to duration since first treatment
and in relation to combined modality treatment, person-years
and any second cancer in an individual at each moment
during follow-up were allocated to the category of the
analysis variable that the individual had reached at that time.
Observed cancers in the cohort were compared to expecta-
tions from sex-, age- and year-specific rates for England and
Wales (Coleman et al., 1986).
National cancer registration rates were not available in
computer readable form for 1970 or 1985-87. National data
for 1971 were therefore used as the comparison for cancer
incidence in the cohort in 1970-71, and 1984 data as the
comparison for 1984-87. Statistical significance of the
observed to expected ratios (relative risks) was based on the
Poisson distribution. Two-sided P values are presented. Tests
for trend in relative risk were based on a likelihood ratio test
statistic (Breslow & Day, 1987), and trend in absolute excess
risk was tested by a method of Smith (unpublished). Relative
risks were adjusted for the potential confounding variables,
period since first treatment, number of courses of treatment
(1 vs 2+) and type of treatment (chemotherapy vs no chemo-
therapy), by Poisson regression techniques using the EGRET
computer package (SERC, 1989).
Absolute excess risks of second cancers were calculated by
subtracting the expected from the observed number of cases,
and dividing by person-years at risk.
Results
During 1970-87, 2853 new patients aged 10 years or more
with Hodgkin's disease entered the BNLI. Seven were ex-
cluded from analysis because they died on the first day of
treatment, and therefore did not contribute any person-days
at risk. This left 2846 patients in the study. Most were
younger than 45 years (73%) and most were male (63%).
Total follow-up was for 17,329 person-years at risk, mainly
in the first 5 years (10,184) and second 5 years (5,172) after
incidence. The patients were followed on average for 6.1
years. Mean follow-up in relation to age and sex, stage and
histology of Hodgkin's disease, and splenectomy status, is
shown in Table I.
One hundred and thirteen second primary cancers other
than Hodgkin's disease occurred in the cohort during follow-
up. A third primary cancer, of the lung, occurred in one
patient, and was not included in the present analyses. The
Table I Number of patients, person-years of follow-up, and mean
follow-up, by age, sex, stage and histology of Hodgkin's disease, and
splenectomy status
Mean
No. of Person-years follow-up
Riskfactor patients offollow-up (years)
Age (years)
<25 890 6052.9 6.8
25-44 1179 7594.7 6.4
45-54 336 1938.9 5.8
55 441 1742.4 4.0
Sex
Male 1790 10967.3 6.1
Female 1056 6361.6 6.0
Stage
I 652 4324.6 6.6
II 847 5507.2 6.5
III 809 4904.6 6.1
IV 536 2588.7 4.8
Histology
Lymphocyte depleted 40 130.5 3.3
Lymphocyte predominant 168 1167.5 6.9
Mixed cellularity 533 2890.8 5.4
Nodular sclerosing I 1317 9277.2 7.0
Nodular sclerosing II 746 3570.8 4.8
Splenectomy
No 1736 7984.0 4.6
Yes 1110 9344.9 8.4
overall relative risk of second cancer in the cohort, compared
to expectations derived from general population rates, was
2.7 (95% CL 2.3-3.3) (Table II). There were significantly
increased risks of leukaemia (relative risk (RR) = 16.0), non-
Hodgkin's lymphoma (RR = 16.8) and lung cancer (RR =
3.8) (Table II) as well as of colon cancer (RR = 3.2; 1.4-6.2;
n = 8), bone cancer (RR = 15.2; 1.8-54.7; n = 2) and thyroid
cancer (RR = 9.4; 1.1-33.9; n = 2) (not in Table). Further
detail, and attributable and cumulative risks of second pri-
mary cancers in the cohort, are given in Swerdlow et al.
(1992). Since numbers of each solid cancer other than lung
cancer were relatively small, they are combined together for
the analyses that follow.
The relative risk of second cancers overall was slightly but
not significantly greater in males than females (Table II). The
relative risk of leukaemia was significantly greater in females
than males, while sex differences for the other sites in Table
II were not significant. Absolute excess risks of second cancer
overall, of lung cancer, and of non-Hodgkin's lymphoma
were greater in males than in females, and of leukaemia was
greater in females than males. Adjusting the comparisons of
relative risk between the sexes for duration of follow-up,
number of courses of treatment, and type of treatment, made
virtually no difference to the results.
Analyses of the sex differences in relative risk by type of
treatment (not presented in table) showed that the overall
male excess resulted mainly from an excess after chemo-
therapy (RR of all malignancies except Hodgkin's disease for
chemotherapy patients, compared to England and Wales
population rates, for males = 3.7 (95% confidence intervals,
2.5-5.2), and for females = 1.9 (0.9-3.5)), while the female
excess for leukaemia resulted particularly from a sex differ-
ence after combined modality treatment (RR females = 59.0
(16.0-150.6); RR males=9.5 (1.1-34.2)).
There was a significant trend in relative risk of second
primary cancers overall with age at first treatment, risk being
higher for younger patients (Table III). This trend was also
highly significant for leukaemia, and for non-lung solid
malignancies. For lung cancer and for non-Hodgkin's lym-
phoma there were not significant trends with age; this
remained the case when the tests were repeated amalgamat-
ing the youngest age-group, in which there were no cases
observed and very small expected numbers, with the next
age-group. Subdivision of the age analyses by type of treat-
ment (not shown in table) was hampered by small numbers
in many of the categories, but did not indicate that the1008 A.J. SWERDLOW et al.
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age-trends described above were restricted to particular treat-
ment types. Adjustment of the relative risks in Table III for
duration of follow-up, number of courses of treatment, and
type of treatment, only marginally affected the results: the
significant trends with age diminished slightly in magnitude,
but remained highly significant.
Absolute excess risks of second cancer overall, of lung
cancer, and of non-Hodgkin's lymphoma, increased greatly
with age (P<0.001) (Table III), whereas for leukaemia and
non-lung solid cancers there was no consistent relation of
absolute excess risk to age.
We repeated the analyses of leukaemia risk by age, restric-
ting the category under analysis to acute or non-lymphocytic
leukaemias (ANLL) (15 cases). The ANLL analyses were
imperfect, and therefore not used for the main analyses,
because histological type and acuteness/chronicity were not
stated for 15% of the leukaemias in the national cancer
registration data set used as the comparison, but were known
for all of the leukaemias in BNLI study patients. We also
conducted the analyses for ANLL restricted to patients who
had received any chemotherapy. In both instances the ana-
lyses showed a similar pattern to that seen in Table III for
leukaemia overall: relative risks decreased highly signifi-
cantly, by slightly more than tenfold, from age under 25
years to age 55 years and over, and absolute risks were about
2-fold lower for the age-groups over 45 years than for the
age-groups younger than this.
Relative risks of second primary cancer overall varied
significantly according to the histological subtype of the
initial Hodgkin's disease (Table IV), although the range of
risks was modest. Risks of non-Hodgkin's lymphoma (NHL)
showed a much larger, significant variation with histology of
the original Hodgkin's disease; greatest risk was after lym-
phocyte predominant Hodgkin's disease (RR = 55.6), and
least with any cases after nodular sclerosing I (RR = 9.8),
with no cases of NHL occurring after the few cases of
lymphocyte depleted Hodgkin's disease. Risks of leukaemia
and of non-lung solid malignancies were also significantly
related to the histology of the initial Hodgkin's disease.
When the relationship was re-tested omitting the cells in the
table with no cases, the relationship for NHL remained
highly significant (P<0.001) while those for leukaemia and
for non-lung solid malignancies ceased to be significant.
Adjustment for duration since first treatment, type of treat-
ment and number of courses of treatment had only a slight
and inconsistent effect on the results.
The relative risk of second primary cancer did not relate to
the stage of Hodgkin's disease (Table V). This conclusion
remained when the relationship was re-tested omitting the
cells in the table (for leukaemia) with no cases, and was also
not affected by adjustment of the risks for duration of
follow-up, number of courses of treatment and type of treat-
ment. Adjusting analyses by treatment type (Swerdlow et al.,
1992) for histology and stage had no consistent effect, and in
no instance where convergence was possible did addition of
these variables have a significant effect.
Risk of second cancers was also not significantly related to
whether or not the patient had undergone splenectomy
(Table VI). The relative risk of leukaemia was somewhat, but
not significantly, greater in patients who had undergone
splenectomy (RR = 19.3) than in those who had not (RR =
13.7). Adjustment for time since first treatment, type of
treatment, and number of courses of treatment, marginally
decreased each of the relative risks of second cancer in
splenectomised compared to non-splenectomised patients,
and the differences between the two groups remained non-
significant.
Discussion
There is now a great deal of evidence that modern intensive
treatment of Hodgkin's disease causes leukaemia and solid
second malignancies (Kaldor et al., 1987; Tucker et al.,
Table IV Relative risks of second primary cancer by histological type of Hodgkin's disease
All other Non-Hodgkin's All malignancies
Lung cancer solid tumours Leukaemia lymphoma except Hodgkin's
RR RR RR RR RR
Histology No. (95% CI) No. (95% CI) No. (95% CI) No. (95% CI) No. (95% CI)
Lymphocyte depleted 8.1 - - - 1.5
(n = 40) 1 (0.2-45.3) 0 0 0 1 (0.0-8.6)
Lymphocyte predominant - 0.4 - 55.6 1.7
(n = 168) 0 1 (0.0-2.2) 0 5 (18.0-129.7)' 6 (0.6-3.6)
Mixed cellularity 2.2 1.4 17.6 22.1 2.5
(n= 533) 6 (1.0-6.0)a 10 (0.7-2.6) 4 (4.8-45.1)c 5 (7.2-51.6)c 25 (1.6-3.7)C
Nodular sclerosing I 4.0 1.8 18.1 9.8 2.8
(n = 1317) 16 (2.3-6.5)c 27 (1.2-2.6)b 9 (8.3 34.3)c 5 (3.2-23.0)c 57 (2.2-3.6)c
Nodular sclerosing II 7.3 1.4 18.4 11.9 3.2
(n= 746) 9 (3.4 13.9)c 7 (0.6-2.9) 3 (3.8-53.8)c 2 (1.4-43.0)a 21 (2.0-4.8)c
All histologiesd 3.8 1.5 16.2 16.9 2.7
(n = 2846) 32 (2.6-5.4)c 45 (1.1-2.0)a 16 9.2-26.2)c 17 (9.9-27.1)c 110 (2.2-3.2)c
X2 heterogeneity 8.44 12.19a 14.05b 24.25c 26.68c
ap<0.05; bp<0.0l; cp<0.00l. dIncluding 42 cases of unknown histology.
Table V Relative risks of second primary cancer by stage of Hodgkin's disease
All other Non-Hodgkin's All malignancies
Lung cancer solid tumours Leukaemia lymphoma except Hodgkin's
RR RR RR RR RR
Stage No. (95% CI) No. (95% CI) No. (95% CI) No. (95% CI) No. (95% CI)
I (n=652) 13 4.6 12 1.3 0 - 4 13.3 29 2.3
(2.4 7.9)c (0.7-2.3) (3.6 34.0)c (1.5-3.2)c
II(n = 847) 10 5.1 16 2.0 5 19.2 5 18.6 36 3.4
(2.5 9.4)C (1.2-3.3)a (6.2-44.7)C (6.0 43.4)C (2.4 4.8)c
III (n= 809) 5 2.3 14 1.7 8 29.2 5 18.1 32 2.9
(0.7-5.3) (0.9-2.9) (12.6- 57.5)C (5.9-42.1)c (2.0-4.I)c
IV (n = 536) 4 2.8 6 1.2 3 18.2 3 18.4 16 2.3
(0.8-7.1) (0.4-2.5) (3.7-53.I)b (3.8-53.8)b (1.3 3.7)b
All stagesd (n =2846) 32 3.8 48 1.6 16 16.0 17 16.8 113 2.7
(2.6 5.4)c (1.2-2. )b (9.2-26.0)c (9.8-26.9)c (2.3 3.3)c X2 trend 1.9 0.004 0.002 0.19 0.02
ap<o.05; bp<0.01; cp<0.001. dIncluding 2 cases of unknown stage.1010 A.J. SWERDLOW et al.
Table VI Relative risks of second primary cancer in relation to splenectomy
All other Non-Hodgkin's All malignancies
Lung cancer solid tumours Leukaemia lymphoma except Hodgkin's
RR RR RR RR RR
No. (95% CI) No. (95% CI) No. (95% CI) No. (950% CI) No. (95% CI)
Splenectomy (n= 1110) 11 3.0 19 1.6 8 19.3 8 18.0 46 2.9
(1.8-6.6)c (1.0-2.5) (8.3- 38.l)c (7.8 35.5)C (2.1 3.9)C
No splenectomy (n = 1736) 21 3.9 29 1.6 8 13.7 9 15.9 67 2.6
(2.4 59)c (1.0-2.2)a (5.9-26.9)c (7.3-30.l)c (2.1 3.4)c
ap< 0.05; bp<0.01; cp<0.001. In no instance is the difference between the splenectomy and no splenectomy risks statistically
significant.
1988), and increasing data on the relation of these risks to
specific treatments (Pedersen-Bjergaard et al., 1987; Tucker et
al., 1988; Boivin & O'Brien, 1988; Kaldor et al., 1990; Swerd-
low et al., 1992). There is considerable uncertainty, however,
on the possible modifying effects of age and sex, and the
histology and stage of Hodgkin's disease, on these risks. Such
analyses need large data sets, but are of importance because
they might indicate that different weight should be given to
the risk of second primary cancers when selecting treatment
for different categories of patient.
We found a greater relative risk of leukaemia (compared
to general population expectations) for women than for men,
but sex was not otherwise related to the relative risk of
second primary cancers. Previous data on the sex ratio of
second malignancies after Hodgkin's disease (Van der Velden
et al., 1988; Henry-Amar et al., 1990) and after other
radiotherapy (National Research Council, 1990) have been
inconsistent.
We found relative risks of second cancers overall greater at
younger ages than at older. This effect was most striking for
leukaemia but significant also for solid cancers. For solid
cancers, the absolute risk generally increased with age,
whereas for leukaemia it did not. Therefore for leukaemia
but not solid cancers, a possible interpretation is that an
approximately constant risk with age on an additive scale
may occur, which appears greater at younger than older ages
when considered on a relative scale, because baseline (general
population) rates are greater at older ages. Most previous
studies have only analysed age-specific risks by comparison
between groups within the study, without allowance for the
difference in risk by age to be expected from general popula-
tion rates. Results of such analyses for leukaemia have been
inconsistent (Tester et al., 1984; Valagussa et al., 1986; Col-
man et al., 1988; Tucker et al., 1988; Van Leeuwen et al.,
1989; Henry-Amar et al., 1990). Analyses of leukaemia rela-
tive risks by age compared to general population expecta-
tions, by van der Velden et al. (1988) and Tucker et al.
(1988), found no relation to age. The difference from our
results appears mainly to arise from a lower relative risk at
older ages in our data than theirs. This does not appear to be
due to less aggressive treatment at older ages in BNLI
patients, since the age-gradient remained unchanged when we
adjusted for treatment parameters. Nor was it due to the
category of leukaemias analysed, since, despite methodo-
logical difficulties, it was clearly present separately for
ANLL, which appears to be the type of leukaemia related to
treatment (Kaldor et al., 1990).
There do not appear to be previous data on solid cancer
relative risks after Hodgkin's disease by age, although Tucker
et al. (1988) commented without analysis on the young age at
treatment of several of their patients with solid second
primary cancers. The age relationship for solid cancers is
likely to be of great practical importance. Unlike leukaemias,
relative risks of solid tumours continue to be sizeably raised
(and indeed may continue to increase) at least 10-20 years,
and probably longer, after first treatment (Kaldor et al.,
1987; Tucker et al., 1988; Henry-Amar et al., 1990; Swerdlow
et al., 1992). Thus although absolute risks of solid tumours
are fairly low in young patients, a continuation of (or in-
crease in) high relative risks in these patients as they grow
older, would translate into a very sizeable absolute risk of
malignancy as background expected rates rise with age. This
emphasises the need for further investigation of long-term
risks, and for continued clinical follow-up of Hodgkin's
disease patients and search for new less-carcinogenic treat-
ment regimes.
We found no relationship of risk of leukaemia or solid
second primary cancers to the histology of the initial Hodg-
kin's disease. Other authors too have found no significant
relation for second leukaemias (Pedersen-Bjergaard et al.,
1987; van der Velden et al., 1988; Kaldor et al., 1990; Henry-
Amar et al., 1990). Risk of NHL, however, was significantly
related to the histology of the original Hodgkin's disease,
with greatest risk after lymphocyte predominant Hodgkin's
disease. Clinical reports previously have noted an apparently
much raised frequency of NHL after lymphocyte predomin-
ant tumours (Miettinen et al., 1983; Bennett et al., 1991). The
only previous analysis of the risk, to our knowledge, also
found greatest NHL risk after lymphocyte predominant Hod-
gkin's disease, although without histology review (Henry-
Amar et al., 1990). Review of the histology of the Hodgkin's
disease and NHL tumours was carried out for the present
study (by Dr M.H. Bennett and K. MacL.), and is of impor-
tance because a possible artefactual reason for an apparent
relationship of NHL risk to particular Hodgkin's disease
histologies would be that the initial tumours might have been
composite ones, containing both Hodgkin's disease and NHL
tissue. On review this was not the case for any of the cases
reported here (Bennett et al., 1991). Second primary NHL
does not appear to relate to the type of treatment of the
Hodgkin's tumour (Swerdlow et al., 1992), but it is possible
that part of the natural history of lymphocyte predominant
Hodgkin's disease is a tendency to progress to NHL (Sun-
deen et al., 1988; Hansmann et al., 1989). Alternatively,
immunological or other features of lymphocyte predominant
Hodgkin's may predispose to NHL.
Risk of second primary cancer was unrelated to the stage
of Hodgkin's disease at presentation. This was also found in
previous studies for second primary leukaemia (Pedersen-
Bjergaard et al., 1987; Van der Velden et al., 1988; Colman et
al., 1988) and solid cancers (Henry-Amar, 1988), at least
after adjusting for variation in treatment by stage. Kaldor et
al. (1990), in a case-control study, found leukaemia risk
lower after stage I than after later stages of Hodgkin's
disease. No leukaemia cases occurred after stage I Hodgkin's
disease in our data, which was in the direction of Kaldor's
findings, although the relationship of stage to risk was not
significant.
Certain recent reports have found a significant raised risk
of leukaemia in Hodgkin's disease patients who have under-
gone splenectomy compared to those who have not (Van der
Velden et al., 1988; Van Leeuwen et al., 1989; Kaldor et al.,
1990), and have suggested that the benefit of splenectomy
needs to be balanced against this potential disbenefit (Van
Leeuwen et al., 1989). We, like some other investigators
(Tucker et al., 1988; Henry-Amar et al., 1990), found a
smaller non-significant increase in leukaemia risk after splen-
ectomy. Adjustment for potentially confounding variables did
not appreciably alter this. There was no suggestion of raised
risk of other malignancies after splenectomy in a previous
analysis (Henry-Amar et al., 1990) or in our data.SECOND PRIMARY CANCER AFTER HODGKIN'S DISEASE 1011
We thank the collaborators in the BNLI whose patients are included
in these analyses, and the regional cancer registries in England and
Wales who assisted in follow-up of patients. We pay tribute to Dr
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